Excerpt From Press Release—October 5, 2000 Genzyme General and Pharming Group N.V., announced today that results from the first two

Chen focused on the phase I/II trials underway at Duke with 3 IIa infants. Average age at diagnosis is 5

Genzyme Corporation and it’s development partner, Pharming N.V., are committed to providing an effective and practical therapy for Pompe disease

The Lancet—July 29, 2000 Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 2000; 356: 397-398 Hannerieke Van den

Genzyme and Pharming to Fund Commercialization Cambridge, Mass., USA, Durham, N.C., USA, and Leiden, the Netherlands, April 19, 2000 –

Pharming’s first Phase II clinical trial for Pompe’s disease finalised, showing survival, skeletal muscle regeneration and overall improvement of heart

New York University Medical Center Frank Martiniuk, Ph.D. A collaborative effort to test animal models with enzyme and gene replacement

Applied Biological Sciences Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified

News Release by Karyn Hede Duke Medical Center News Office August 2, 1999 Using a modified virus to deliver a

The first IPA Conference was held on July 2-4, 1999, in Naarden, the Netherlands. The meeting was attended by over

The following status statement was released by Synpac (North Carolina), Inc., on June 30, 1999 The following status statement was

The following article by Laura Spinney appears in BioMednews Reports (6- 25-99,#57) Glycogen storage disease type II causes enlargement of

Orphan Drug Designation A drug becomes an “orphan” when it receives orphan designation from the Office of Orphan Products Development,

Following is background information and a Q & A released by the Pharming/Genzyme LLC on important issues concerning clinical trials

Leiden, the Netherlands/Cambridge, Mass., October 14, 1998—Pharming Group N.V. (Easdaq: PHAR), the Netherlands biopharmaceutical company, and the American biotechnology company

Human Gene Therapy 9:1609-1616 (July 20, 1998) Mary Ann Liebert, Inc. Adenovirus-Mediated Transfer of Human Acid Maltase Gene Reduces Glycogen

National Institutes of Health Paul Plotz, M.D., Nina Raben, M.D., Ph.D. Nina Raben, M.D., Ph.D., NIH Research Chemist, visited the

Human Molecular Genetics, January 1998 “Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease” by A.

Johns Hopkins University Barry J. Byrne, M.D., Ph.D. Paul D. Kessler, M.D. The following is a summary of the publication

Johns Hopkin’s University scientists have successfully used a virus to supply a missing gene and its enzyme product to muscle

News Archives

Post Categories